Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation
The HIV-1 pandemic is a significant challenge to the field of medicine. Despite advancements in antiretroviral (ART) development, 38 million people worldwide still live with this disease without a cure. A significant barrier to the eradication of HIV-1 lies in the persistently latent pool that estab...
Main Authors: | Angel Lin, Weam Othman Elbezanti, Alexis Schirling, Adel Ahmed, Rachel Van Duyne, Simon Cocklin, Zachary Klase |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.663793/full |
Similar Items
-
Benzodiazepines Drive Alteration of Chromatin at the Integrated HIV-1 LTR
by: Weam Elbezanti, et al.
Published: (2020-02-01) -
The Effect of Mutating RUNX1 Binding Site on HIV-1 Replication and Novel HIV-1 Latency Reversal through Using Clinically Prescribed Benzodiazepines
by: Elbezanti, Weam Othman
Published: (2019) -
Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017-12-01) -
Molecular Monitoring of RUNX1-RUNX1T1 Transcript Level in Acute Myeloblastic Leukemias on Treatment
by: LL Girshova, et al.
Published: (2016-10-01) -
Use of triazolam and alprazolam as premedication for general anesthesia
by: Doyun Kim, et al.
Published: (2015-08-01)